Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.68 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RGS12 | O14924 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169925 | 0.93 | FAAH (0.64) | MAPTFAAHSMN1; SMN2TP53RXFP1 | |
| SCHEMBL2168110 | 0.93 | FAAH (0.65) | MAPTFAAHSMN1; SMN2PLA2G2AMEN1 | |
| SCHEMBL2168258 | 0.93 | FAAH (0.65) | MAPTFAAHSMN1; SMN2PLA2G2AMEN1 | |
| SCHEMBL2999877 | 0.91 | MAPT (0.61) | MAPTFAAHSMN1; SMN2TP53RXFP1 | |
| SCHEMBL2170352 | 0.91 | FAAH (0.73) | MAPTFAAHSMN1; SMN2PLA2G2AMEN1 | |
| SCHEMBL2170160 | 0.90 | FAAH (0.62) | MAPTFAAHSMN1; SMN2TP53PLA2G2A | |
| SCHEMBL2168224 | 0.89 | MAPT (0.58) | MAPTFAAHTP53MEN1KMT2A | |
| SCHEMBL2168630 | 0.88 | FAAH (0.64) | MAPTFAAHPLA2G2AMEN1RGS12 | |
| SCHEMBL2168730 | 0.88 | FAAH (0.62) | MAPTFAAHSMN1; SMN2PLA2G2AMEN1 | |
| SCHEMBL2169306 | 0.88 | FAAH (0.62) | MAPTFAAHSMN1; SMN2PLA2G2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | UNITED STATES OF AMERICA (US) | 2013-08-29 | — | — | US | claimed |
| WO-2011123719-A2 | USE OF FAAH INHIBITORS FOR TREATING ABDOMINAL, VISCERAL AND PELVIC PAIN | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| WO-2011085216-A2 | USE OF FAAH INHIBITORS FOR TREATING PARKINSON'S DISEASE AND RESTLESS LEGS SYNDROME | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | WO | claimed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | claimed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | claimed |
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | UNITED STATES OF AMERICA (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | QUEST VENTURES LTD. (GB) | 2013-06-13 | — | — | US | disclosed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| WO-2011123719-A2 | USE OF FAAH INHIBITORS FOR TREATING ABDOMINAL, VISCERAL AND PELVIC PAIN | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224151-A1 | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain | FAAH, FAAH2, PNLIP | MAPT 4229/4885FAAH 1/4885SMN1; SMN2 3297/4885 |
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | MAPT 997/4885FAAH 109/4885SMN1; SMN2 3581/4885 |
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | MAPT 2737/4885FAAH 1/4885SMN1; SMN2 4055/4885 |
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | FAAH, FAAH2, MGLL | MAPT 3165/4885FAAH 1/4885SMN1; SMN2 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.